Effect of an Optimized Treatment With Insulin on Platelet Reactivity After Discharge in Patients With an Acute Coronary Syndrome and Hyperglycemia

被引:4
|
作者
Vivas, David [1 ]
Garcia-Rubira, Juan C. [1 ]
Bernardo, Esther [1 ]
Angiolillo, Dominick J. [1 ]
Martin, Patricia [2 ]
Calle, Alfonso [2 ]
Nunez-Gil, Ivan [1 ]
Macaya, Carlos [1 ]
Fernandez-Ortiz, Antonio [1 ]
机构
[1] Hosp Clin San Carlos, Inst Cardiovasc, Madrid 28040, Spain
[2] Hosp Clin San Carlos, Serv Endocrinol, Madrid 28040, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2014年 / 67卷 / 01期
关键词
Platelets; Acute coronary syndrome; Diabetes mellitus; ACUTE MYOCARDIAL-INFARCTION; TYPE-2; DIABETES-MELLITUS; GLUCOSE CONTROL; FUNCTION PROFILES; STRESS HYPERGLYCEMIA; GLYCEMIC CONTROL; THERAPY; CLOPIDOGREL; DISEASE; RISK;
D O I
10.1016/j.rec.2013.05.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: Intensive glucose control with insulin in patients with an acute coronary syndrome reduces platelet reactivity during hospitalization, compared to conventional control. However, the effect of strict, long-term glucose control on platelet reactivity in these patients remains uncertain. Methods: This is a prospective, randomized trial evaluating the effects of optimized glucose control (target glucose, 80-120 mg/dL) with insulin, compared with conventional control (target glucose, <180 mg/dL), on platelet reactivity after hospital discharge in patients with an acute coronary syndrome and hyperglycemia. The primary endpoint was assessment of platelet aggregation after stimulation with adenosine diphosphate 20 mu M at 12-month follow-up. Results: One hundred four patients were randomized to optimized management (n=53) or conventional management (n=51). There were no differences between groups in baseline characteristics or platelet function. After 12 months of follow-up, blood glucose levels were significantly lower in the optimized treatment group (104 vs 119 mg/dL; P<.001). However, platelet aggregation following adenosine diphosphate 20 mu M stimulation showed no differences between the groups (54.2% [14.3%] vs 55.1% [18.3%] respectively; P=.81). There were no significant differences for other platelet function tests. Conclusions: Long-term optimized glucose control with insulin in patients with an acute coronary syndrome did not result in a reduction in platelet reactivity compared to conventional control. (C) 2013 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S. L. All rights reserved.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 50 条
  • [21] Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome
    Lee, Sarolta
    Hizoh, Istvan
    Kovacs, Andrea
    Horvath, Zsofia
    Kiss, Nora
    Toth-Zsamboki, Emese
    Kiss, Robert Gabor
    PLATELETS, 2016, 27 (02) : 159 - 167
  • [22] Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor
    Gaglia, Michael A., Jr.
    Lipinski, Michael J.
    Lhermusier, Thibault
    Steinvil, Arie
    Kiramijyan, Sarkis
    Pokharel, Shreejana
    Torguson, Rebecca
    Angiolillo, Dominick J.
    Wallentin, Lars
    Storey, Robert F.
    Waksman, Ron
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 119 (08): : 1135 - 1140
  • [23] Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in acute coronary syndrome patients on dual antiplatelet treatment
    Becatti, M.
    Fiorillo, C.
    Gori, A. M.
    Marcucci, R.
    Paniccia, R.
    Giusti, B.
    Violi, F.
    Pignatelli, P.
    Gensini, G. F.
    Abbate, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 644 - 644
  • [24] Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome
    Tatarunas, Vacis
    Kupstyte-Kristapone, Nora
    Zvikas, Vaidotas
    Jakstas, Valdas
    Zaliunas, Remigijus
    Lesauskaite, Vaiva
    SCIENTIFIC REPORTS, 2020, 10 (01) : 3175
  • [25] Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome
    Vacis Tatarunas
    Nora Kupstyte-Kristapone
    Vaidotas Zvikas
    Valdas Jakstas
    Remigijus Zaliunas
    Vaiva Lesauskaite
    Scientific Reports, 10
  • [26] MEAN PLATELET VOLUME AND PLATELET COUNT: OVERSEEN MARKERS OF HIGH ON-TREATMENT PLATELET REACTIVITY AND WORSE OUTCOME IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Jakl, M.
    Sevcik, R.
    Ceral, J.
    Vojacek, J.
    Fatorova, I.
    Horacek, J.
    Pudil, R.
    HAEMATOLOGICA, 2012, 97 : 419 - 419
  • [27] Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients
    Bonello, Laurent
    Laine, Marc
    Baccini, Veronique
    Frere, Corinne
    THROMBOSIS RESEARCH, 2017, 152 : 38 - 40
  • [28] Mean platelet volume and platelet count: overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome
    Jakl, Martin
    Sevcik, Robert
    Ceral, Jiri
    Fatorova, Ilona
    Horacek, Jan M.
    Vojacek, Jan
    ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY, 2014, 14 (01): : 85 - 86
  • [29] The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndrome: Mediation by superoxide production, resolution with intensive insulin administration
    Worthley, MI
    Holmes, AS
    Willoughby, SR
    Kucia, AM
    Heresztyn, T
    Stewart, S
    Chirkov, YY
    Zeitz, CJ
    Horowitz, JD
    CIRCULATION, 2003, 108 (17) : X - X
  • [30] Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity
    Samardzic, Jure
    Krpan, Miroslav
    Skoric, Bosko
    Pasalic, Marijan
    Petricevic, Mate
    Milicic, Davor
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (04) : 459 - 469